<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555240</url>
  </required_header>
  <id_info>
    <org_study_id>PRUA1GR-2013-00000203</org_study_id>
    <nct_id>NCT03555240</nct_id>
  </id_info>
  <brief_title>Regional Registry-based Biobank Development and Pharmacogenetic Analysis in Rheumatoid Arthritis</brief_title>
  <acronym>RABiobank</acronym>
  <official_title>Regional Registry-based Biobank Development and Pharmacogenetic Analysis: Synergistic Strategies Driving Towards Personalized Medicine in Rheumatoid Arthritis Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regione Emilia Romagna - Italy within PRU-Liberati project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this project is the building-up of an integrated model of multidisciplinary research
      tools to support large-scale and high-quality disease-based studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologics have revolutionized rheumatoid arthritis (RA) management, with a great impact on
      patient that justifies treatment with these high-cost drugs. Nevertheless, timing and proper
      therapeutic decision making remain the main challenge in clinical practice.

      Pharmacogenetics approach might open promising perspectives, increasing our understanding on
      genetic-related drug efficacy. Nevertheless, to ensure feasibility and reliability of
      translational applications of this strategy in clinical practice, large population-based
      research studies represent a crucial key step.

      Objectives

      Major aim of this project is the building-up of an integrated model of multidisciplinary
      research tools to support large-scale and high-quality disease-based studies. The main
      targets of this proposal will be:

        -  to develop a disease-based biobank, integrated with already established Emilia-Romagna
           regional RA Registry, providing a large-scale prospective collection and storing of
           multiple biological samples

        -  to perform a pharmacogenetic study analyzing a panel of gene variants potentially
           influencing the response to Tumor Necrosis Factor (TNF) blockers. Methods

        -  Biobank development. A step-wise plan will be considered for: designing biobank
           governance frame-work, defining Standard Operating Procedures, implementing information
           system resources. All these procedures will be applied for collecting, processing and
           storing biological samples of patients included in regional RA registry.

        -  Pharmacogenetic study. A panel of candidate gene variants will be studied in genomic DNA
           from 300 patients enrolled in the regional RA registry. The association between
           genotypes and response to biological drugs will be assessed by data-mining approach, and
           a predictive model will be defined. Expected Results This proposal will create a
           disease-based biobank, tightly integrated with the already established Emilia-Romagna
           regional RA Registry, and pave the way towards personalized therapy applications in
           Rheumatology.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 27, 2014</start_date>
  <completion_date type="Actual">September 28, 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biobank creation</measure>
    <time_frame>through study completion, an average of 5 years</time_frame>
    <description>Collection of biological samples from patients included into Emilia Romagna Rheumatoid Arthritis Registry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of genes potentially predictive of response to biological drugs</measure>
    <time_frame>at 12 Months</time_frame>
    <description>Pharmacogenetics analysis of genes involved in the response to biological drugs</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Patient with Rheumatoid Arthritis</arm_group_label>
    <description>Patient with Rheumatoid Arthritis living in the Emilia Romagna Italian region whom samples will be collected for the Biobank creation and Pharmacogenetic analysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biobank creation and Pharmacogenetic analysis</intervention_name>
    <description>Collection of biological samples (blood, serum, plasma) form patient enrolled in the Emilia Romagna rheumatoid arthritis registry and genotyping genomic DNA samples, and assessing the association between genotypes and response to biological drugs, using multivariate and data-mining approaches that includes also clinical and demographic parameters.</description>
    <arm_group_label>Patient with Rheumatoid Arthritis</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with residents in Emilia Romagna Region, partecipating to the regional rheumatoid
        arthritis registy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of Arthritis Rheumatoid according American College of Rheumatology (ACR)1987
             or according ACR/European League Against Rheumatism (EULAR) 2010 criteria

          2. Patients with new diagnosis or patients already diagnosed with active disease [with
             Disease Activity Score (DAS) 28 &gt; o = 4,2] or patients switching therapy

          3. Male and female patients of minimum 18 years old

          4. Provision of informed consent

        Exclusion Criteria:

        1) Patients living outside Emilia Romagna region
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elisa Assirelli, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rizzoli Orthopedic Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Unit IRCCS Orthopedic Rizzoli Institute</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Internal Medicine Department of Internal Medicine and Nephrology diseases and Aging</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Department of Internal Medicine Buflini Hospital</name>
      <address>
        <city>Cesena</city>
        <state>FC</state>
        <zip>47521</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Genetics Unit, Dept. of Biomedical and Specialty Surgery</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit S.Anna University Hospital</name>
      <address>
        <city>Ferrara</city>
        <state>FE</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Unit, Internal Medicine Department Morgagni Hospital</name>
      <address>
        <city>Forl√¨</city>
        <state>Fo</state>
        <zip>47121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unit of Internal Medicine, Medical Internistic Department Ospedale Santa maria delle croci</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Rheumatology Azienda Ospedaliera-IRCC S, Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine Infermis' Hospital</name>
      <address>
        <city>Rimini</city>
        <state>RN</state>
        <zip>47921</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Laboratory of Immunorheumatology and Tissue Regeneration IRCC Rizzoli Orthopedic Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. Clin Rheumatol. 2011 Mar;30 Suppl 1:S3-8. doi: 10.1007/s10067-010-1634-9. Epub 2011 Feb 26. Review.</citation>
    <PMID>21359507</PMID>
  </reference>
  <reference>
    <citation>Hamilton SR, Chatrian GE, Mills RP, Kalina RE, Bird TD. Cone dysfunction in a subgroup of patients with autosomal dominant cerebellar ataxia. Arch Ophthalmol. 1990 Apr;108(4):551-6.</citation>
    <PMID>2322158</PMID>
  </reference>
  <reference>
    <citation>Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther. 2012 Jan;91(1):30-43. doi: 10.1038/clpt.2011.278. Epub 2011 Dec 14. Review.</citation>
    <PMID>22166850</PMID>
  </reference>
  <reference>
    <citation>Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology (Oxford). 2012 Dec;51 Suppl 6:vi37-43. doi: 10.1093/rheumatology/kes283. Review.</citation>
    <PMID>23221586</PMID>
  </reference>
  <reference>
    <citation>Prajapati R, Plant D, Barton A. Genetic and genomic predictors of anti-TNF response. Pharmacogenomics. 2011 Nov;12(11):1571-85. doi: 10.2217/pgs.11.114. Review.</citation>
    <PMID>22044414</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 18, 2018</study_first_submitted>
  <study_first_submitted_qc>May 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>November 8, 2019</last_update_submitted>
  <last_update_submitted_qc>November 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Plan</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 20, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/40/NCT03555240/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

